1. Home
  2. TSE vs CMMB Comparison

TSE vs CMMB Comparison

Compare TSE & CMMB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Trinseo PLC

TSE

Trinseo PLC

HOLD

Current Price

$0.23

Market Cap

8.3M

Sector

Industrials

ML Signal

HOLD

Logo Chemomab Therapeutics Ltd.

CMMB

Chemomab Therapeutics Ltd.

HOLD

Current Price

$1.88

Market Cap

9.1M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
TSE
CMMB
Founded
2010
2004
Country
United States
Israel
Employees
N/A
N/A
Industry
Major Chemicals
Biotechnology: Pharmaceutical Preparations
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
8.3M
9.1M
IPO Year
2014
2023

Fundamental Metrics

Financial Performance
Metric
TSE
CMMB
Price
$0.23
$1.88
Analyst Decision
Hold
Buy
Analyst Count
1
1
Target Price
$1.00
$25.00
AVG Volume (30 Days)
749.8K
74.1K
Earning Date
01-01-0001
01-01-0001
Dividend Yield
N/A
N/A
EPS Growth
50.40
101.67
EPS
N/A
0.04
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
$2.53
N/A
P/E Ratio
N/A
$45.75
Revenue Growth
N/A
N/A
52 Week Low
$0.23
$0.87
52 Week High
$4.66
$3.86

Technical Indicators

Market Signals
Indicator
TSE
CMMB
Relative Strength Index (RSI) 27.26 56.77
Support Level N/A $1.48
Resistance Level $0.51 $2.80
Average True Range (ATR) 0.06 0.18
MACD -0.01 0.05
Stochastic Oscillator 0.33 78.46

Price Performance

Historical Comparison
TSE
CMMB

About TSE Trinseo PLC

Trinseo PLC is a materials company and manufacturer of latex and plastics products. The company's operating segments include Latex Binders, Americas Styrenics, Engineered Materials, and Polymer Solutions. Maximum revenue is generated from its Polymer Solutions segment, which consists of various polymers, the majority of which are for automotive, building, and construction applications. The product offerings of this segment include ABS, styrene-acrylonitrile, polystyrene, and polycarbonate products, which are marketed through brands like Magnum and Styron. Geographically, the company generates maximum revenue from Europe, followed by the United States, Asia-Pacific, and the Rest of the world.

About CMMB Chemomab Therapeutics Ltd.

Chemomab Therapeutics Ltd is a clinical-stage biotech company, focusing on the discovery and development of therapeutics for fibrosis-related diseases with large unmet needs. The company's candidate, CM-101, is a monoclonal antibody that targets CCL24 and was shown to interfere with the underlying biology of liver, skin, and lung fibrosis using a novel and differentiated mechanism of action. CM-101 has demonstrated the potential to treat multiple severe and life-threatening fibrotic and inflammatory diseases. It is advancing three Phase 2 clinical trials in parallel for CM-101, treating rare fibrotic conditions.

Share on Social Networks: